Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything' - Featured image
Finance

Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything'

Jim Cramer commented on Eli Lilly's GLP-1 pill, anticipating a revolutionary impact. He also assessed other portfolio holdings, including Taiwan Semi, Chevron, SL Green, and Microsoft, providing insights into their respective sectors.

Shotlee·December 23, 2025·Updated Jan 27, 2026·2 min read
Share:

Jim Cramer on Eli Lilly's GLP-1 Pill

Jim Cramer offered insights on Eli Lilly and Company (NYSE:LLY) when responding to questions about portfolio diversification. The caller noted their top five holdings included LLY, SLG, MSFT, CVX, and TSM.

Cramer stated, "Really interesting setup here. Okay, so, Taiwan Semi is the actual fab that makes the chips for Broadcom, makes chips for AMD, makes chips for, yes, NVIDIA. Alright, that's in Taiwan. Very important. Eli Lilly is the company that has GLP-1 Mounjaro, very powerful drug. They're going to have a pill form next year that's going to revolutionize everything. I think the stock's going up another $500 billion, I kid you not. Chevron is my favorite large oil company with a good yield. That's run by Mike Wirth. SL Green is a company that's come back from the dead basically, and it's a REIT... in New York. I'm not really, I don't really want a REIT in New York, but that's what they do. And then Microsoft, okay, Mr. Softee, we know it's business-to-business software with the consumer side of it too. So I'm going to say, this is semi, this is software, this is drug, this is oil, and this is retail, and I'm going to bless all of them. Now, would I keep SL Green? I do happen to see Federal Realty coming back, and I'd like to see Don Wood in that portfolio instead of SL Green."

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

Eli Lilly and Company (NYSE:LLY) focuses on the development and marketing of medications for various conditions, including diabetes, obesity, oncology, immunology, and neuroscience, among other chronic diseases. Health tracking apps like Shotlee can help monitor health data relevant to these conditions.

Cramer's analysis provided a comprehensive overview of the caller's investment choices, highlighting the potential of Eli Lilly's pharmaceutical advancements and the importance of diversification across different sectors.

Original source: Yahoo! Finance

View original article →
#Jim Cramer#Eli Lilly#GLP-1 pill#LLY#stock analysis#investment
  1. Home
  2. Blog
  3. Jim Cramer: Eli Lilly's GLP-1 Pill Will 'Revolutionize Everything'

Related Articles

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report
Metabolic Health

73M Overweight Urban Indians, GLP-1 Awareness <5%: Kantar Report

Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community